Medibiofarma

Executive Summary

Medibiofarma is a clinical-stage Spanish biotechnology company focused on developing first-in-class small molecule therapies for complex diseases, including cancer, Crohn's disease, and neurodegeneration. Founded in 2013 (or 2016 per description), the company employs a target-based medicinal chemistry approach to modulate clinically validated targets, with a core focus on enabling T-cell infiltration in tumors. Operating under a virtual R&D model, Medibiofarma partners for non-core activities, allowing efficient resource allocation. The company is currently in Phase 2 clinical development, targeting key unmet needs in immuno-oncology and chronic inflammatory conditions. While no financial details are disclosed, Medibiofarma's pipeline and strategic partnerships position it as a promising player in the Spanish biotech landscape, though its private status and early-stage programs imply higher risk.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 data readout for lead cancer asset (T-cell infiltration enhancer)40% success
• Q4 2025Orphan drug designation for Crohn's disease candidate60% success
• Q1 2026Corporate partnership or licensing deal for neurodegeneration program35% success